Introduction {#sec0005}
============

As the number of patients with infectious diseases in the elderly increases, the long-term half-life and its excellent tissue transferability increases the frequency of use of ceftriaxone. It is commonly prescribed against various serious infections such as meningitis and bacteremia as well as lower respiratory tract, complicated urinary tract, skin, bone, and joint infections. During intravenous ceftriaxone treatment, 85%--95% of the drug would remain in the blood for a long time by binding to serum albumin. Approximately 55% of the drug is excreted by the kidneys, whereas the other 45% is excreted through the gallbladder [@bib0005].

The incidence of ceftriaxone-induced biliary pseudolithiasis in children is relatively high, and it has been reported to be 10.1%--46.5% in previous studies [@bib0010], [@bib0015]. Because the unusual occurrence of abdominal symptoms in patients with biliary pseudolithiasis is reportedly 0%--19% [@bib0020], [@bib0025], our case was observed to have symptoms. It is thought that many patients are overlooked in actual clinical practice.

Case report {#sec0010}
===========

An 89-year-old woman had been seen at another clinic. She had a nonproductive cough and felt to have pneumonia. Her cardiac and renal function were deteriorating with a NT-pro-BNP 8537 pg/mL and creatinine 6.46 mg/dL. She was felt to be malnourished (serum albumin 2.2 g/dL). Abdominal computed tomography (CT) at the time of admission did not show gallbladder stones ([Fig. 1](#fig0005){ref-type="fig"}A). Because signs of pneumonia were recognized in the chest X-ray image, the patient was started on ceftriaxone, 1 g per day (every 24 h) (in consideration of her renal function), from the day of hospitalizationFig. 1The abdominal horizontal slices of computed tomographic scanning. A: On the admission day. The pictures did not admit gallbladder stones. B: On the day 7 of admission. Abdominal computed tomographic scanning showed gallbladder stones very clearly. C: On the day 15 of admission. The concentration of gallbladder stones became faint, and biliary pseudolithiasis showed improvement tendency.Fig. 1

On day 7 of admission, tenderness in the right hypochondral region and epigastralgia were observed, and abdominal CT very clearly showed gallbladder stones ([Fig. 1](#fig0005){ref-type="fig"}B). Ceftriaxone-induced biliary pseudolithiasis was diagnosed and the antibacterial agent was changed to sulbactam/cefoperazone mixture 1 g per day (every 24 h) from day 7 to day 15 of admission. Then, we changed to tazobactam/piperacillin 4.5 g (every 12 h) because pneumonia did not improve completely.

Abdominal CT performed on day 15 of admission showed that the concentration of gallbladder stones had decreased and that biliary pseudolithiasis had improved ([Fig. 1](#fig0005){ref-type="fig"}C).

Diet steadily improved, although by day 18, she remained on a suboptimal diet. Maintenance infusion (normal saline) was continued, but the renal function remained severely impaired as detected by both blood urea nitrogen and serum creatinine levels. The pneumonia gradually worsened along with the respiratory condition. She continued to deteriorate and died on day 27 of admission.

Discussion {#sec0015}
==========

Bile acids and ceftriaxone may use the same transport pathway, so biliary secretion of ceftriaxone could inhibit bile acids secretion. Whereas ceftriaxone is 85 to 95% bound to albumin in blood, 45% of unchanged is excreted in bile, therefore, ceftriaxone concentration in bile is 20-to 150-fold that in the serum [@bib0030], [@bib0035]. When the concentration of ceftriaxone within the gallbladder exceeds a threshold, it is known to precipitate by binding to calcium ions secreted with the bile acids. Because ceftriaxone, like bilirubin, can precipitate with calcium, ceftriaxone-associated biliary sludge is thought to be composed mainly of calcium-ceftriaxone complexes. Afterward, the precipitated sludge forms stones and may finally develop into ceftriaxone-induced biliary pseudolithiasis. Therefore, ceftriaxone-induced biliary sludge is not derived from cholesterol monohydrate crystals or calcium bilirubinate. The formation of this calcium-ceftriaxone complex is detected by ultrasound studies in the form of a gallstone or biliary sludge [@bib0040]. Pseudobiliary stones are considered structurally unstable; therefore, they can easily be excreted with bile [@bib0045].

Onset of pseudobiliary stones varies from 2 to 22 days after starting treatment with ceftriaxone [@bib0010], [@bib0020], [@bib0050], [@bib0055], [@bib0060]. Kimura reported that stones appeared on day 30 after the end of 12 days of ceftriaxone administration [@bib0025]. Generally, spontaneous exclusion (or disappearance) of the stones occurs relatively quickly after stopping ceftriaxone administration, but the period varies from 2 days to 5 months after the discontinuation of ceftriaxone administration [@bib0015], [@bib0020], [@bib0025], [@bib0040], [@bib0050], [@bib0060], [@bib0065]. In an *in vitro* study, at doses of ceftriaxone greater than or equal to 2 g, precipitation of ceftriaxone could occur, and the development of ceftriaxone-induced biliary sludge could be because of poor solubility that occurs in patients receiving a high-dose treatment (greater than or equal to 2 g) [@bib0030].

Cases of ceftriaxone-associated biliary pseudolithiasis in adults worldwide are reported in [Table 1](#tbl0005){ref-type="table"}. Since it is anticipated that the incidence of pseudolithiasis increases at more and more elderly with low activity and high risks of dehydration, careful observation for early detection such as cholecystitis and pancreatitis is necessary in patients receiving ceftriaxone. [Table 1](#tbl0005){ref-type="table"} shows that many complications such as cholecystitis and pancreatitis occurred, and ceftriaxone-associated biliary pseudolithiasis disappeared within approximately two months after stopping its administration. Because discontinuation of ceftriaxone almost eliminates gallstones, considering biliary pseudolithiasis may lead to the avoidance of excessive additional examinations and invasive treatments such as cholecystectomy. Prevention of biliary pseudolithiasis requires shortening the duration of administration of ceftriaxone, sufficient maintenance infusion for prevention of dehydration, and avoiding excessive rest. It is believed that ceftriaxone causes the formation of gallbladder stones at a relatively high frequency, and when abdominal symptoms occur, it is necessary to promptly scrutinize the gallbladder and start appropriate treatment. It is reasonable to follow the progress by ultrasound or CT for two months after the administration of ceftriaxone.Table 1Reported cases of ceftriaxone-associated pseudolithiasis in adult.Table 1YearAuthorAgeSexInfection TypeDoseDuration (days)ComplicationSubsequent ManagementOutcomeTime to Disapperrance11991Zinberg73FSepsis2 g/day19CholecystitisCTRX stopResolution28 days21992Kirejczyk19FLyme disease2 g q24hr14CholecystitisCTRX stopResolution21 days31996Lorberboym54FMeningitis2 g/day42CholecystitisCTRX stopResolution14 days41999Famularo71FRadiculae abscess2 g/day10Cholecystitis/PancreatitisCholecystectomyNon-Resolution--52005Bickford53MMeningitis2 g q12hr7Obstructive jaundiceCTRX stopResolution14 days72009Becker68MBrain abscess2 g q12hr?CholecystitisCholecystectomyResolution--82009Rienstra64MAortitis2 g q12hr21Obstructive jaundiceReduction of CTRX to1gResolution?92009Sasaki35FColon diverticulitis2 g q24hr12PancreatitisCTRX stopResolution2 months102009Tsuzaki24MEndocarditis2 g q12hr46CholecystitisCholecystectomyNon-Resolution--112011Rivera49MGastroenteritis1 g q24hr4Obstructive jaundiceCTRX stopResolution12 days122011Choi21MColon diverticulitis2 g q24hr5NoneCTRX stopResolution1 month132011Choi22MPneumonia2 g q24hr12NoneCTRX stopResolution1 month142012Nakagawara65MEnteritis2 g/day7CholecystitisDrainageResolution14 days152012Hanata15FMeningitis4 g/day28CholecystitisCTRX stopResolution19 days162013Tomoda47FColon diverticulitis2 g q24hr8CholecystitisCTRX stopResolution6 days172013Imoto66MMeningitis4 g/day22CBD stoneDrainageResolution21 days182013Imoto67MMeningitis4 g/day23CholecystitisCTRX stopResolution42 days192013Tanahashi54FColon diverticulitis2 g/day7Cholecystitis/CholangitisDrainageResolution33 days202014Tanaka83FRenal abscess2 g q12hr36Cholecystitis/CholangitisCholecystectomyResolution--212014Okazaki19FUrinary tract infection2 g/day7CholecystitisCTRX stopResolution12 months222015Shima79FBronchial pneumonia1 g q48hr13CholecystitisCTRX stopResolution48 days232016Niwa23FColon diverticulitis2 g/day6CholecyctitisCTRX stopResolution1 month242016Niwa76FSubcutaneous abscess2 g/day8CholecystitisCTRX stopResolution17 days252016Niwa63MHepatic abscess3--4 g/day20CholecystitisCTRX stopResolution2 months262016Niwa93MPneumonia2 g/day7CholecystitisCTRX stopResolution?272016Dohmen76MPneumonia1 g q12hr8CholecystitisCTRX stopResolution22days[^1]

Ceftriaxone is a parenteral cephalosporin with a broad-spectrum activity against gram-positive and gram-negative bacteria [@bib0005]. The drug has enhanced stability against various β-lactamase-producing bacteria [@bib0020], and a reportedly prolonged elimination half-life of 6 to 9 h. On the other hand, because the mean half-life during dialysis is 16 h, it has been reported that ceftriaxone is hardly removed during dialysis [@bib0070]. When ceftriaxone is administered to patients with renal insufficiency or on dialysis, it may be necessary to adjust the dosage of ceftriaxone, keeping in mind that high concentrations of ceftriaxone in blood and bile may cause biliary pseudolithiasis. It is necessary to start treatment early and it is necessary to adjust medical treatment for the pseudolithiasis cases with renal failure. Even when ceftriaxone administration was discontinued in our case, the gallbladder stone did not completely disappear because of renal function deterioration. When ceftriaxone is administered to patients with renal insufficiency or dialysis, it is necessary to adjust the dose while keeping in mind that rising blood and bile concentrations may cause pseudolithiasis.

After initiation of ceftriaxone treatment, biliary pseudolithiasis was noted at a significantly greater frequency in the fasting and bed rest groups. Rapid decrease in oral intake, leading to long-term fasting and weight loss, is a typical risk factor for biliary pseudolithiasis [@bib0055]. Since malnutrition, renal impairment, and sepsis due to pneumonia are risk factors for pseudolithiasis, prevention of these is important to suppress gallstone development. During ceftriaxone treatment, attention should be paid to the required oral intake and level of bed rest following the start of therapy, depending on the disease pathology.
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[^1]: \*Abbreviations: CBD: common bile duct, CTRX: ceftriaxone.
